Cancers in BRCA1 and BRCA2 carriers and in women at high risk for breast cancer: MR imaging and mammographic features

Radiology

Volumn 252, Issue 2, 2009, Pages 358-368

  Gilbert, Fiona J ^a   Warren, Ruth M L ^b   Kwan Lim, Gek ^c   Thompson, Deborah J ^d   Eeles, Ros A ^e   Evans, D Gareth ^f   Leach, Martin O ^c,e  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e Institute of Cancer Genetics   (United Kingdom)

^f ST MARY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN, HUMAN; PROTEIN P53;

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; CANCER SCREENING; CLINICAL TRIAL; DIAGNOSTIC IMAGING; FEMALE; GENE MUTATION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE; PRIORITY JOURNAL; TUMOR VOLUME; BREAST TUMOR; GENETIC PREDISPOSITION; GENETICS; HETEROZYGOTE; METHODOLOGY; RISK ASSESSMENT; RISK FACTOR; UNITED KINGDOM;

ADULT; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GREAT BRITAIN; HETEROZYGOTE; HUMANS; MAGNETIC RESONANCE IMAGING; MAMMOGRAPHY; RISK ASSESSMENT; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 70249150718     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2522081032     Document Type: Article

References (19)

1. Leach MO, Boggis CR, Dixon AK, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005;365(9473):1769-1778. [Published correction appears in Lancet 2005;365(9474):1848.]
2. Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004;351:427-437. (Pubitemid 38988592)
3. Warner E, Plewes DB, Hill KA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004;292(11):1317-1325. (Pubitemid 39223222)
4. Kuhl CK, Schrading S, Leutner CC, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 2005;23(33):8469-8476. (Pubitemid 46260243)
5. Sardanelli F, Podo F, D'Agnolo G, et al. Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT study): interim results. Radiology 2007;242(3):698-715. (Pubitemid 46310082)
6. Lakhani SR, Van De Vijver MJ, Jacquemier J, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002;20(9):2310-2318. (Pubitemid 34441658)
7. Lakhani SR, Reis-Filho JS, Fulford L, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 2005;11(14):5175-5180. (Pubitemid 41003703)
8. Tilanus-Linthorst M, Verhoog L, Obdeijn IM, et al. A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography. Int J Cancer 2002;102(1):91-95. [Published correction appears in Int J Cancer 2002;102(6):665.]
9. Veltman J, Mann R, Kok T, et al. Breast tumor characteristics of BRCA1 and BRCA2 gene mutation carriers on MRI. Eur Radiol 2008;18(5):931-938.
10. Schrading S, Kuhl CK. Mammographic, US, and MR imaging phenotypes of familial breast cancer. Radiology 2008;246(1):58-70.
11. Brown J, Buckley D, Coulthard A, et al. Magnetic resonance imaging screening in women at genetic risk of breast cancer: imaging and analysis protocol for the UK multicentre study. UK MRI Breast Screening Study Advisory Group. Magn Reson Imaging 2000;18(7):765-776. (Pubitemid 30769056)
12. Warren RM, Thompson D, Pointon LJ, et al. Evaluation of a prospective scoring system designed for a multicenter breast MR imaging screening study. Radiology 2006;239(3):677-685. (Pubitemid 43830602)
13. Warren RM, Pointon L, Thompson D, et al. Reading protocol for dynamic contrast-enhanced MR images of the breast: sensitivity and specificity analysis. Radiology 2005;236(3):779-788. (Pubitemid 41170838)
14. Gilbert FJ, Warren RM, Kessar P, Padhani AR, Boggis CR, MARIBS Advisory Group. Comparison of MRI and mammography imaging features in BRCA1 and BRCA2 cancers found in the UK MARIBS trial [abstr]. In: Radiological Society of North America scientific assembly and annual meeting program. Oak Brook Ill: Radiological Society of North America, 2005; 621.
15. Tilanus-Linthorst MM, Kriege M, Boetes C, et al. Hereditary breast cancer growth rates and its impact on screening policy. Eur J Cancer 2005;41(11):1610-1617. (Pubitemid 40981844)
16. Tilanus-Linthorst MM, Obdeijn IM, Hop WC, et al. BRCA1 mutation and young age predict fast breast cancer growth in the Dutch, United Kingdom, and Canadian magnetic resonance imaging screening trials. Clin Cancer Res 2007;13(24):7357-7362.
17. Familial breast cancer: the classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care (NICE guideline CG041). Sheffield, England: National Collaborating Centre for Primary Care, 2006; 1-75.
18. McIntosh A, Shaw C, Evans G, et al. Clinical guidelines and evidence review for the classification and care of women at risk of familial breast cancer. (NICE guideline CG014). Sheffield, England: National Collaborating Centre for Primary Care, 2004;1-166.
19. Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007;57(2):75-89. [Published correction appears in CA Cancer J Clin 2007;57(3):185.]